Wenli Yu

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Structural Basis

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Science (New York, N.Y.)

This page only lists publications with an associated author ORCID identifier.

Publications

Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K Barry Sharpless, Ian A Wilson, Dennis W Wolan
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proceedings of the National Academy of Sciences of the United States of America 121 (22) (2024)
Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K Barry Sharpless, Ian A Wilson, Dennis W Wolan
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proceedings of the National Academy of Sciences of the United States of America 121 (22) (2024)
Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K Barry Sharpless, Ian A Wilson, Dennis W Wolan
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proceedings of the National Academy of Sciences of the United States of America 121 (22) (2024)
Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K Barry Sharpless, Ian A Wilson, Dennis W Wolan
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proceedings of the National Academy of Sciences of the United States of America 121 (22) (2024)
Seiya Kitamura, Ting-Hui Lin, Chang-Chun David Lee, Akihiro Takamura, Rameshwar U Kadam, Ding Zhang, Xueyong Zhu, Lucas Dada, Emiko Nagai, Wenli Yu, Yao Yao, K Barry Sharpless, Ian A Wilson, Dennis W Wolan
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proceedings of the National Academy of Sciences of the United States of America 121 (22) (2024)
S Momsen Reincke, Meng Yuan, Hans-Christian Kornau, Victor Max Corman, Scott van Hoof, Elisa Sánchez-Sendin, Melanie Ramberger, Wenli Yu, Yuanzi Hua, Henry Tien, Marie Luisa Schmidt, Tatjana Schwarz, Lara Maria Jeworowski, Sarah E Brandl, Helle Foverskov Rasmussen, Marie A Homeyer, Laura Stöffler, Martin Barner, Désirée Kunkel, Shufan Huo, Johannes Horler, Niels von Wardenburg, Inge Kroidl, Tabea M Eser, Andreas Wieser, Christof Geldmacher, Michael Hoelscher, Hannes Gänzer, Guenter Weiss, Dietmar Schmitz, Christian Drosten, Harald Prüss, Ian A Wilson, Jakob Kreye
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science (New York, N.Y.) 375 (6582) (2022)
Meng Yuan, Hejun Liu, Nicholas C Wu, Chang-Chun David Lee, Xueyong Zhu, Fangzhu Zhao, Deli Huang, Wenli Yu, Yuanzi Hua, Henry Tien, Thomas F Rogers, Elise Landais, Devin Sok, Joseph G Jardine, Dennis R Burton, Ian A Wilson
Structural basis of a shared antibody response to SARS-CoV-2. Science (New York, N.Y.) 369 (6507) (2020)